← board
GRI
distress 6/10 · elevated risk$1.49+1%today-98% from 52w high
Lead: idiopathic pulmonary fibrosis · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$11M
Runway
0.9 yrs
Shares 1y
-30%
Price & events
-72.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.6%
1D
-3.3%
1W
-20.0%
1M
-38.2%
3M
-73.6%
6M
-97.4%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $2.64M
- Volume
- 1.07K
- 52 Week Range
- $1.47 – $63.28
- Total Shares
- 1.77M
- Float Shares
- 1.77M
- Short %
- 6.49%
- % Held by Insiders
- 0.46%
- % Held by Institutions
- 2.80%
- RVOL
- 0.01x
- Beta
- -0.67
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- Q3 2025readoutPhase 2GRI-0621 · Topline data from Phase 2a biomarker studySEC 8-K
- Q1 2025readoutPhase 2GRI-0621 · Report topline results from Phase 2a biomarker studySEC 8-K
- Q4 2024readoutPhase 2GRI-0621 · Report interim data from Phase 2a biomarker studySEC 8-K
- August 20-22, 2024conferencedata presentationsecondaryGRI-0621 · Oral presentation at the 8th Annual Idiopathic Pulmonary Fibrosis SummitSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-01Ascendiant CapitalBuy
- 2026-03-11Ascendiant CapitalBuy
- 2025-12-08Ascendiant CapitalBuy
- 2025-09-22Ascendiant CapitalBuy
- 2025-06-11HC Wainwright & Co.Buy
- 2025-05-27Ascendiant CapitalBuy
Competitors — idiopathic pulmonary fibrosis
- ABBVAbbVie Inc.$451.1B · D2
- UTHRUNITED THERAPEUTICS Corp$22.3B · D0
- TRVITrevi Therapeutics, Inc.$2.5B · D1
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- AVLNAvalyn Pharma Inc.$1.3B · D4
- MNKDMANNKIND CORP$1.2B · D0
- CTNMContineum Therapeutics, Inc.$334M · D2
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- RNTXRein Therapeutics, Inc.$72M · D10
- TVRDTvardi Therapeutics, Inc.$25M · D4
Recent news
- 2026-06-25GRI Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-18FDA gives GRI Bio a rare-disease boost for lung scarring drug - Stock Titan
- 2026-06-18GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewswire
- 2026-06-18GRI Bio's GRI-0621 gains FDA Orphan Drug Designation for treating fatal lung disease IPF - Pluang
- 2026-05-27GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key Support - Algorithmic Stock Picks - dars.gov.et
- 2026-05-27GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key Support - Sentiment Shift - dars.gov.et
- 2026-05-18GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase - Yahoo Finance
- 2026-05-14GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.